Moderna today announced the administration of first COVID-19 vaccine doses to participants between the ages of 6 months and 12 years old as part of a phase 2/3 clinical trial. 

The trial will investigate the vaccine’s effectiveness and safety in 6,750 healthy pediatric participants. For this study, Moderna will investigate two dosing levels for those ages 2 to 12, and three dosing levels for those aged 6 months to 2 years old.

Related News Articles

Headline
A mix-and-match vaccine regimen is permissible for international travelers entering the U.S., according to updated Centers for Disease Control and Prevention…
Headline
Treatment with subcutaneous interferon beta-1a plus remdesivir was not superior to treatment with remdesivir alone in a clinical trial that enrolled 969…
Headline
Two doses of the Pfizer vaccine are 93% effective at preventing COVID-19 hospitalization among children aged 12 to 18, according to a study at 19…
Headline
The Centers for Disease Control and Prevention yesterday released an operational planning guide for pediatric COVID-19 vaccination and preliminary information…
Headline
Available data support the safety and effectiveness of the Johnson & Johnson COVID-19 vaccine for emergency use authorization as a booster dose in…
Headline
A Food and Drug Administration advisory panel today voted unanimously to recommend an extra Moderna booster dose for certain individuals. The Vaccines and…